Evidence map›Paper›PMID 30573507›Full record

ArticleHaematologica2019

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.

Audrey Bidet, Stéphanie Dulucq, Thomas Smol, Alice Marceau-Renaut, Stéphane Morisset, Valérie Coiteux, Marie-Pierre Noël-Walter, Franck-Emmanuel Nicolini, Isabelle Tigaud, Isabelle Luquet and 24 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. [The significance of non-Ph chromosome in chronic myelogenous leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 20 institutions in 1 country.

Audrey BidetLaboratoire d'Hématologie, CHU Bordeaux.
Stéphanie DulucqLaboratoire d'Hématologie, CHU Bordeaux.
Thomas SmolInstitut de Génétique Médicale, Hôpital Jeanne de Flandre, CHU Lille.
Alice Marceau-RenautInstitut d'Hématologie, Centre de Biologie Pathologie Génétique, CHU Lille.
Stéphane MorissetDépartement d'Hématologie, Centre Léon Bérard, Lyon.
Valérie CoiteuxService des Maladies du Sang, Hôpital Claude Huriez, CHU Lille.
Marie-Pierre Noël-WalterService des Maladies du Sang, Hôpital Claude Huriez, CHU Lille.
Franck-Emmanuel NicoliniDépartement d'Hématologie, Centre Léon Bérard, Lyon.
Isabelle TigaudLaboratoire de Cytogénétique et de Biologie Moléculaire, Service d'Hématologie Biologique - CBPAS, GHS - Hospices Civils de Lyon, Pierre-Bénite Cedex, France.
Isabelle LuquetLaboratoire d'Hématologie, Plateau Technique Hématologie-Oncologie, Institut Universitaire du Cancer de Tolouse Oncopole.
Stéphanie StruskiLaboratoire d'Hématologie, Plateau Technique Hématologie-Oncologie, Institut Universitaire du Cancer de Tolouse Oncopole.
Baptiste GaillardLaboratoire Central d'Hématologie, Hôpital Robert Debré, Reims.
Dominique PentherLaboratoire de Génétique Oncologique, Centre de Lutte Contre le Cancer Henri Becquerel, Rouen.
Sylvie TondeurLaboratoire d'Hématologie-Cytogénétique, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne Cedex 2.
Nathalie NadalLaboratoire de Génétique Chromosomique et Moléculaire, Plateau Technique de Biologie, CHU de Dijon.
Eric HermetService d'Hématologie Clinique, CHU Estaing, Clermont-Ferrand.
Lauren VéronèseLaboratoire de Cytogénétique, CHU Estaing, Clermont-Ferrand.
Delphine RéaService Clinique des Maladies du Sang, Hôpital St Louis, Paris.
Carine GervaisLaboratoire Régional de Cytogénétique Hématologique d'Alsace, CHU de Haute Pierre, Strasbourg Cedex.
Olivier TheisenLaboratoire de Cytogénétique Hématologique, Plateau Technique Hôtel Dieu, Nantes.
Christine TerréLaboratoire de Cytogénétique du Centre Hospitalier Valence, Le Chesnay.
Pascale Cony-MakhoulService d'Hématologie, Centre Hospitalier Annecy-Genevois, Epagny Metz-Tessy.
Christine LefebvreUnité de Génétique des Hémopathies, Institut de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble Cedex 9.
Jean-Baptiste GaillardUnité de Génétique Médicale et Cytogénétique, CHU de Nîmes.
Isabelle RadfordLaboratoire de Cytogénétique, Hôpital Necker - Enfants Malades, Paris.
Anne-Laure VervaekeLaboratoire d'Hématologie, CHU Bordeaux.
Carole BarinLaboratoire de Cytogénétique Onco-Hématologie, Hôpital Bretonneau, Tours.
Elise ChapiroService d'Hématologie Biologique, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris et Sorbonne Université, Paris.
Florence Nguyen-KhacService d'Hématologie Biologique, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris et Sorbonne Université, Paris.
Gabriel EtienneDépartement d'Hématologie, Institut Bergonié, Bordeaux, France.
Claude PreudhommeCentre de Recherche Jean-Pierre Aubert, UMR-S 1172, Université de Lille.
François Xavier MahonDépartement d'Hématologie, Institut Bergonié, Bordeaux, France.
Catherine Roche-LestienneInstitut de Génétique Médicale, Hôpital Jeanne de Flandre, CHU Lille catherine.roche@chru-lille.fr.
Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Intergroup of Chronic Myeloid Leukemia (Fi-LMC)
Centre Léon Bérard · FRHôpital Claude Huriez · FRInstitut Bergonié · FRInstitut universitaire du cancer de Toulouse Oncopole · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Annecy Genevois · FRCentre Hospitalier de Valence · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Hospitalier Universitaire de Saint-Étienne · FRCentre Hospitalier Universitaire de Tours · FRGénétique Médicale & Génomique Fonctionelle · FRHôpital Jeanne de Flandre · FRHôpital Necker-Enfants Malades · FRHôpital Robert-Debré · FRHôpital Saint-Louis · FRHospices Civils de Lyon · FRInserm · FRInstitut de Biologie de Lille · FRLaboratoire de Génétique Cellulaire · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clonal chromosome abnormalities in Philadelphia-negative cells could concern chronic myeloid leukemia patients treated by tyrosine kinase inhibitors. The European LeukemiaNet distinguishes -7/del(7q) abnormalities as a "warning". However, the impact of clonal chromosome abnormalities, and specifically those of -7/del(7q), in Philadelphia-negative cells on clinical outcomes is unclear and based on case-reports showing morphological dysplasia and increased risk of acute myeloid leukemia, suggesting the coexistence of chronic myeloid leukemia and high-risk myelodysplastic syndrome. The aim of this study was to determine whether the impact of -7/del(7q) clonal chromosome abnormalities in Philadelphia-negative cells on the clinical outcome is different from that of other types of abnormalities, and we argue for an underlying associated high-risk myelodysplastic syndrome. Among 102 chronic myeloid leukemia patients with clonal chromosome abnormalities in Philadelphia-negative cells with more than a median of 6 years of follow up, patients with -7/del(7q) more frequently had signs of dysplasia, a lower cumulative incidence of deep molecular response and often needed further treatment lines, with the consequent impact on event-free and progression-free survival. Morphological features of dysplasia are associated with myelodysplastic syndrome/acute myeloid leukemia mutations and compromise the optimal response to tyrosine kinase inhibitors, irrespectively of the type of clonal chromosome abnormalities in Philadelphia-negative cells. However, mutation patterns determined by next-generation sequencing could not clearly explain the underlying high-risk disease. We hereby confirm the pejorative prognostic value of -7/del(7q) clonal chromosome abnormalities in Philadelphia-negative cells and suggest that myelodysplastic features constitute a warning signal that response to tyrosine kinase inhibitors may be less than optimal.

Indexed as

Chromosome AberrationsChromosomes, Human, Pair 7AllelesChromosome DeletionDisease ProgressionFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHigh-Throughput Nucleotide SequencingHumansIn Situ Hybridization, FluorescenceLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMetaphaseMiddle AgedMolecular Targeted Therapy

Identifiers

PMID30573507
PMCPMC6545846
OpenAlexW2905138986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.